Corcept Therapeutics (NASDAQ:CORT) Upgraded at Truist Financial

Truist Financial upgraded shares of Corcept Therapeutics (NASDAQ:CORT) to a strong-buy rating in a report issued on Wednesday morning,Zacks.com reports.

Several other research analysts have also issued reports on CORT. Canaccord Genuity Group raised their price target on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, January 23rd. Wolfe Research downgraded Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective on the stock. in a report on Wednesday, December 31st. HC Wainwright lowered their price objective on Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday. UBS Group began coverage on Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 target price for the company. Finally, Zacks Research downgraded Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $77.67.

Corcept Therapeutics Trading Down 2.4%

Shares of CORT stock opened at $37.60 on Wednesday. Corcept Therapeutics has a 52-week low of $28.66 and a 52-week high of $117.33. The stock has a market cap of $4.00 billion, a price-to-earnings ratio of 45.85 and a beta of 0.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. The firm has a fifty day moving average of $37.53 and a 200-day moving average of $60.76.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The business had revenue of $202.13 million for the quarter, compared to the consensus estimate of $254.94 million. During the same period in the previous year, the business posted $0.26 earnings per share. Corcept Therapeutics’s revenue was up 11.1% on a year-over-year basis. On average, equities research analysts forecast that Corcept Therapeutics will post 1.36 earnings per share for the current fiscal year.

Insider Activity at Corcept Therapeutics

In other news, Director G Leonard Baker, Jr. purchased 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was purchased at an average cost of $33.14 per share, with a total value of $3,314,000.00. Following the acquisition, the director directly owned 1,146,631 shares of the company’s stock, valued at approximately $37,999,351.34. This trade represents a 9.55% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider William Guyer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $40.87, for a total transaction of $817,400.00. Following the completion of the transaction, the insider owned 1,235 shares in the company, valued at approximately $50,474.45. This trade represents a 94.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 86,198 shares of company stock valued at $3,552,769 in the last ninety days. Insiders own 20.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. boosted its holdings in shares of Corcept Therapeutics by 438.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 65,797 shares of the biotechnology company’s stock worth $2,290,000 after acquiring an additional 53,574 shares in the last quarter. Corient Private Wealth LLC increased its holdings in Corcept Therapeutics by 9.3% during the 4th quarter. Corient Private Wealth LLC now owns 7,035 shares of the biotechnology company’s stock valued at $245,000 after purchasing an additional 600 shares in the last quarter. SHP Wealth Management acquired a new stake in Corcept Therapeutics during the 4th quarter valued at $72,000. Caitong International Asset Management Co. Ltd bought a new position in Corcept Therapeutics in the 4th quarter valued at $8,757,000. Finally, Virtu Financial LLC acquired a new position in Corcept Therapeutics in the fourth quarter worth $456,000. Institutional investors own 93.61% of the company’s stock.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer is a material commercial catalyst that triggered the earlier sharp rally; approval creates a new revenue pathway and is the primary reason investors re‑rated the stock this week. FDA approval report
• Positive Sentiment: Broker/analyst support: Wolfe Research upgraded CORT (from underperform to peer‑perform) and other brokers (Truist, Canaccord) have issued bullish/strong‑buy views or raised targets, which can sustain buying interest as the market models new sales upside. Wolfe Research upgrade
• Neutral Sentiment: Market structure/volatility: trading halts and large intraday prints accompanied the approval-driven move — expect continued high volume and price swings as investors reprice expectations for launch and uptake. Market reaction coverage
• Neutral Sentiment: Consensus/ratings mix: some outlets show a “moderate buy” brokerage consensus; analysts remain mixed on valuation as the market weighs launch potential vs. prior execution and study data. Broker consensus report
• Negative Sentiment: Legal risk: multiple law firms have filed shareholder alerts and class actions alleging that Corcept misled investors about regulatory issues and patent matters; these suits (and the referenced FDA rejection / federal court patent loss claims) create potential liability, discovery risk and distraction for management. Hagens Berman class‑action alert
• Negative Sentiment: Insider selling: a recent disclosed sale by an insider reduced holdings significantly; while not proof of negative outlook, such sales can weigh on sentiment when paired with litigation headlines. Insider sale filing
• Negative Sentiment: Analyst divergence / forecast cuts: some firms have tempered long‑term estimates or issued cautious notes (e.g., a pessimistic forecast from HC Wainwright in recent coverage), underscoring uncertainty around peak sales and reimbursement. HC Wainwright coverage

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.